Key clinical point: CAR T cells directed to HER2 can treat some forms of advanced sarcomas.
Major finding: Two of 10 patients had durable complete remissions.
Study details: Phase 1 trial in 10 patients with sarcomas of bone and soft tissues.
Disclosures: Development of the CAR T-cell construct is supported by the Cancer Prevention & Research Institute of Texas, Stand Up to Cancer, the St. Baldrick’s Foundation, Cookies for Kids’ Cancer, Alex’s Lemonade Stand, and a grant from the National Institutes of Health. Dr. Navai and Dr. Azad reported having no disclosures relevant to the work.
Navai SA et al. AACR 2019, Abstract LB-147